United States - English - NLM (National Library of Medicine)

dispensing solutions, inc. - ramipril (unii: l35jn3i7sj) (ramiprilat - unii:6n5u4qfc3g) - ramipril 10 mg - ramipril capsules usp are indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. ramipril capsules usp are contraindicated in patients who are hypersensitive to this product or any other ace inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ace inhibitor). ingestion of a single 10 mg oral dose of ramipril resulted in undetectable amounts of ramipril and its metabolites in breast milk. however, because multiple doses may produce low milk concentrations that are not predictable from a single dose, do not use ramipril in nursing mothers. safety and effectiveness in pediatric patients have not been established. irreversible kidney damage has been observed in very young rats given a single dose of ramipril. of the total number of patients who received ramipril in us clinical studies of ramipril 11% were ≥65 years of age while 0.2% were ≥75 years of age. no overall differences in effectiveness or safety were observed between

United States - English - NLM (National Library of Medicine)

dr. reddy's laboratories limited - ramipril (unii: l35jn3i7sj) (ramiprilat - unii:6n5u4qfc3g) - ramipril 1.25 mg - ramipril capsules are indicated for the treatment of hypertension. it may be used alone or in combination with thiazide diuretics. ramipril capsules are contraindicated in patients who are hypersensitive to this product or any other ace inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ace inhibitor). pregnancy categories c (first trimester) and d (second and third trimesters) [see  w a rnings and precautions (5.6) ]. ingestion of a single 10 mg oral dose of ramipril resulted in undetectable amounts of ramipril and its metabolites in breast milk. however, because multiple doses may produce low milk concentrations that are not predictable from a single dose, do not use ramipril in nursing mothers. safety and effectiveness in pediatric patients have not been established. irreversible kidney damage has been observed in very young rats given a single dose of ramipril. of the total number of patients who received ramipril in u.s. clinical studies of ramipril, 11% were ≥65 ye

United States - English - NLM (National Library of Medicine)

avkare, inc. - ramipril (unii: l35jn3i7sj) (ramiprilat - unii:6n5u4qfc3g) - ramipril 5 mg - ramipril capsules, usp are indicated for the treatment of hypertension. they may be used alone or in combination with thiazide diuretics. ramipril capsules are contraindicated in patients who are hypersensitive to this product or any other ace inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ace inhibitor). pregnancy categories c (first trimester) and d (second and third trimesters) [ see warnings and precautions ( 5.6 ) ]. ingestion of a single 10 mg oral dose of ramipril resulted in undetectable amounts of ramipril and its metabolites in breast milk. however, because multiple doses may produce low milk concentrations that are not predictable from a single dose, do not use ramipril in nursing mothers. safety and effectiveness in pediatric patients have not been established. irreversible kidney damage has been observed in very young rats given a single dose of ramipril. of the total number of patients who received ramipril in u.s. clinical

United States - English - NLM (National Library of Medicine)

lupin pharmaceuticals, inc. - ramipril (unii: l35jn3i7sj) (ramiprilat - unii:6n5u4qfc3g) - ramipril 1.25 mg - ramipril capsules are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program's joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. the largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmhg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). these considerations may guide selection of therapy. ramipril capsules may be used alone or in combination with thiazide diuretics. ramipril capsules is indicated in patients 55 years or older at high risk of developing a major cardiovascular event because of a history of coronary artery disease, stroke, peripheral vascular disease, or diabetes that is accompanied by at least one other cardiovascular risk factor (hypertension, elevated total cholesterol levels, low hdl levels, cigarette smoking, or documented microalbuminuria), to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes. ramipril capsules can be used in addition to other needed treatment (such as antihypertensive, antiplatelet, or lipid-lowering therapy) [see clinical studies (14.2)]. ramipril capsules are indicated in stable patients who have demonstrated clinical signs of congestive heart failure within the first few days after sustaining acute myocardial infarction. administration of ramipril capsule to such patients has been shown to decrease the risk of death (principally cardiovascular death) and to decrease the risks of failure-related hospitalization and progression to severe/resistant heart failure [see clinical studies (14.3)] . ramipril is contraindicated in patients who are hypersensitive to this product or any other ace inhibitor (e.g., a patient who has experienced angioedema during therapy with any other ace inhibitor). ramipril capsules are contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). do not administer ramipril capsules within 36 hours of switching to or from sacubitril/valsartan, a neprilysin inhibitor [see warnings and precautions (5.1)]. do not co-administer ramipril with aliskiren: - in patients with diabetes pregnancy category d use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. when pregnancy is detected, discontinue ramipril as soon as possible. these adverse outcomes are usually associated with use of these drugs in the second and third trimester of pregnancy. most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. appropriate management of maternal hypertension during pregnancy is important to optimize outcomes for both mother and fetus. in the unusual case that there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system for a particular patient, apprise the mother of the potential risk to the fetus. perform serial ultrasound examinations to assess the intra-amniotic environment. if oligohydramnios is observed, discontinue ramipril unless it is considered life-saving for the mother. fetal testing may be appropriate, based on the week of pregnancy. patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury. closely observe infants with histories of in utero exposure to ramipril for hypotension, oliguria, and hyperkalemia [see use in specific populations (8.4)] . ingestion of a single 10 mg oral dose of ramipril resulted in undetectable amounts of ramipril and its metabolites in breast milk. however, because multiple doses may produce low milk concentrations that are not predictable from a single dose, do not use ramipril in nursing mothers. neonates with a history of in utero exposure to ramipril if oliguria or hypotension occurs, direct attention toward support of blood pressure and renal perfusion. exchange transfusions or dialysis may be required as a means of reversing hypotension and/or substituting for disordered renal function. ramipril, which crosses the placenta, can be removed from the neonatal circulation by these means, but limited experience has not shown that such removal is central to the treatment of these infants. safety and effectiveness in pediatric patients have not been established. irreversible kidney damage has been observed in very young rats given a single dose of ramipril. of the total number of patients who received ramipril in u.s. clinical studies of ramipril, 11.0% were ≥65 years of age while 0.2% were ≥75 years of age. no overall differences in effectiveness or safety were observed between these patients and younger patients, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but a greater sensitivity of some older individuals cannot be ruled out. one pharmacokinetic study conducted in hospitalized elderly patients indicated that peak ramiprilat levels and area under the plasma concentration-time curve (auc) for ramiprilat are higher in older patients. a single-dose pharmacokinetic study was conducted in hypertensive patients with varying degrees of renal impairment who received a single 10 mg dose of ramipril. patients were stratified into four groups based on initial estimates of creatinine clearance: normal (>80 ml/min), mild impairment (40 to 80 ml/min), moderate impairment (15 to 40 ml/min), and severe impairment (<15 ml/min). on average, the auc0-24h for ramiprilat was approximately 1.7-fold higher, 3.0-fold higher, and 3.2-fold higher in the groups with mild, moderate, and severe renal impairment, respectively, compared to the group with normal renal function. overall, the results suggest that the starting dose of ramipril should be adjusted downward in patients with moderate-to-severe renal impairment.

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - ramipril (unii: l35jn3i7sj) (ramiprilat - unii:6n5u4qfc3g) - ramipril 2.5 mg - ramipril capsules are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program's joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety of pharmacologic classes and with different

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - ramipril, quantity: 10 mg - tablet, uncoated - excipient ingredients: sodium stearylfumarate; pregelatinised maize starch; sodium bicarbonate; microcrystalline cellulose; hypromellose - treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension. post mi heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmhg or diastolic blood pressure >90mmhg (or an antihypertensive treatment); total cholesterol >5.2mmol/l; hdl cholesterol <0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - ramipril, quantity: 5 mg - tablet, uncoated - excipient ingredients: sodium bicarbonate; microcrystalline cellulose; sodium stearylfumarate; hypromellose; pregelatinised maize starch - treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension. post mi heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmhg or diastolic blood pressure >90mmhg (or on antihypertensive treatment); total cholesterol >5.2mmol/l; hdl cholesterol <0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - ramipril, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: pregelatinised maize starch; sodium stearylfumarate; microcrystalline cellulose; hypromellose; sodium bicarbonate - treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension. post mi heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmhg or diastolic blood pressure >90mmhg (or on antihypertensive treatment); total cholesterol >5.2mmol/l; hdl cholesterol <0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - ramipril, quantity: 1.25 mg - tablet, uncoated - excipient ingredients: sodium bicarbonate; pregelatinised maize starch; hypromellose; microcrystalline cellulose; sodium stearylfumarate - treatment of hypertension. data are currently not available to support the use of ramipril in renovascular hypertension. post mi heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmhg or diastolic blood pressure >90mmhg (or on antihypertensive treatment); total cholesterol >5.2mmol/l; hdl cholesterol <0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

United States - English - NLM (National Library of Medicine)

st. mary's medical park pharmacy - ramipril (unii: l35jn3i7sj) (ramiprilat - unii:6n5u4qfc3g) - ramipril 5 mg - ramipril capsules, usp are indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure education program's joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (jnc). numerous antihypertensive drugs, from a variety of pharmacologic classes and with diffe